首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1604459

胰臟癌症治療市場:各癌症類型，各治療類型，各終端用戶，各地區，機會，預測，2017年～2031年

Pancreatic Cancer Treatment Market Assessment, By Cancer Type, By Treatment Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日期: 2024年12月04日 | 出版商:

Market Xcel - Markets and Data | 英文 247 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄圖表

2024-2031年預測期間，全球胰臟癌治療市場規模將以14.40%的複合年增長率擴大，從2023年的25.2億美元增至2031年的73.9億美元。市場成長的推動因素包括胰臟癌患者數量的增加、主要醫療保健公司對研發活動的投資增加以及主要製藥公司加強藥物開發。胰臟癌盛行率的增加是由多種因素造成的，包括肥胖、飲酒、不健康的生活方式和遺傳因素。

全球胰臟癌治療市場的快速擴張也歸因於對治療胰臟癌的有效治療方案的需求不斷增加、治療技術的進步以及人們對胰臟癌的認識不斷增強。胰臟癌的高死亡率是由於症狀檢測和晚期診斷有限，迫切需要創新和有效的治療方法。

此外，領先的公司和製藥公司正在大力投資開發潛在的癌症突破性治療方法，為全球胰臟癌治療市場創造利潤豐厚的成長機會。去年，禮來公司、阿斯特捷利康公司和百時美施貴寶公司在放射性藥物合作和研究合作方面花費了約 100 億美元。製藥公司相信，直接向腫瘤提供放射線將是癌症治療的下一個突破。

放射性藥物的工作原理是尋找癌細胞上的特定生物標記物，並將放射性物質附著到附著在其上的目標分子上。同樣，2023年12月，諾華公司向中國的放射性製藥設施投資約8,500萬美元（6億元）。目前，該公司正在探索新的聯合療法、配體和同位素，不僅針對前列腺癌和胃腸道胰腺神經內分泌腫瘤，還針對肺癌、大腸癌、乳腺癌和胰腺癌。對計劃產能擴張的投資預計將加強管道開發，加強現有產品組合，為市場推出做好準備，並加速新療法的生產。

本報告提供全球胰臟癌症治療市場相關調查，提供市場概要，以及各癌症類型，各治療類型，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

前五名市場領導的競爭矩陣
前五名參與企業的SWOT分析
前10名市場參與企業的形勢
- AstraZeneca PLC
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited

第21章策略性建議

第22章諮詢方式和免責聲明

簡介目錄圖表

Product Code: MX12328

Global pancreatic cancer treatment market is projected to witness a CAGR of 14.40% during the forecast period 2024-2031, growing from USD 2.52 billion in 2023 to USD 7.39 billion in 2031. The market's growth is bolstered by the rising cases of pancreatic cancer, increasing investments in research and development activities by leading healthcare organizations, and growing drug development efforts by leading pharmaceutical companies. The increasing prevalence of pancreatic cancer can be attributed to various factors, including obesity, alcohol consumption, unhealthy lifestyle, and genetic factors, among others.

The rapid expansion of the global pancreatic cancer treatment market can also be attributed to the rising requirement for effective therapeutic options for managing pancreatic cancer, advancements in treatment technologies, and rising awareness about the condition. The limited symptom detection and late-stage diagnosis of the condition contribute to the high mortality rate of pancreatic cancer, thus creating an urgent requirement for innovative and effective treatments.

Additionally, leading market players and pharmaceutical companies are significantly investing in developing potential cancer breakthroughs, providing lucrative growth opportunities to the global pancreatic cancer treatment market. Over the past year, Eli Lilly and Company, AstraZeneca PLC, and Bristol-Myers Squibb Company have spent approximately USD 10 billion on radiopharmaceutical partnerships and collaborations. Pharmaceutical companies believe that delivering radiation directly to tumors will be the next breakthrough in cancer treatment. Radiopharmaceuticals work by attaching the targeting molecules that search and attach to specific biomarkers on the cancer cells with the radioactive material. Similarly, in December 2023, Novartis AG invested approximately USD 85 million (600 million yuan) in a radioligand facility in China. Currently, the company is exploring new combination therapies, ligands, and isotopes to look beyond prostate cancer and gastroenteropancreatic neuroendocrine tumors and into lung, colon, breast, and pancreatic cancer. The investment towards the planned capacity expansion is expected to bolster pipeline development, strengthen the existing portfolio, prepare for launches, and accelerate the production of novel therapies.

Rising Prevalence of Pancreatic Cancer Boosts Market Demand

The growing burden of the condition in different regions across the globe is one of the major factors bolstering the global pancreatic cancer treatment market demand. With the increasing prevalence of risk factors for pancreatic cancer across the globe, the cases of pancreatic cancer continue to rise, augmenting the requirement for effective therapeutic solutions. As per the estimates of the World Cancer Research Fund International, in 2022, there were more than 510,992 new cases of pancreatic cancer across the globe. Pancreatic cancer has a high mortality rate; because of this, healthcare systems worldwide are focusing on addressing the condition, and the development of effective therapeutic solutions for the disease is becoming a priority.

Increasing Investments in Research Activities Support Market Expansion

The rising investments in research activities in different research institutions across the globe to support the development of therapies for treating pancreatic cancer are expected to influence the market's expansion positively. Investments towards research and development activities are rapidly increasing to address the unmet requirements of pancreatic cancer, with a wide range of research organizations focusing on combination treatments and innovative therapies. Additionally, a significant increase in explore clinical trials exploring new drug candidates with the potential to improve patient outcomes, including immunotherapies and targeted therapies, are being witnessed, further supporting the market's expansion. Moreover, various non-profit and government organizations are also actively funding new therapies for pancreatic cancer. In May 2024, Walter and Eliza Hall Institute of Medical Research received a USD 8 million investment to create a dedicated research center and spearhead new treatments for pancreatic cancer in Australia. The Hemstritch Centre of Excellence for Pancreatic Cancer Research will provide a leading team of clinicians and scientists with funding to make progress in pancreatic cancer treatments, considered the second deadliest cancer in Australia. Such investments are expected to support the development of the next generation of therapies and provide lucrative growth opportunities for the market.

Chemotherapy Accounts for Significant Market Share

The growth of the segment can be attributed to the rising cases of pancreatic cancer, as chemotherapy is used as the first line of treatment for the condition. Cases of pancreatic cancer are usually diagnosed at an advanced stage, where treatments are limited, and chemotherapy is the primary treatment option available for the management of symptoms and controlling the progression of the disease. Although pancreatic cancer is often unresponsive to various treatments, several chemotherapies have been shown to prolong survival and slow down disease progression.

In September 2024, Silexion Therapeutics announced the results from the phase 2 PROTACT trial (NCT01676259). The trial showed that adding siG12D LODER to the standard-of-care chemotherapy improved overall survival and generated responses compared to chemotherapy alone in patients with KRAS G12D/V mutations.

Meanwhile, radiation therapy is expected to grow significantly over the forecast period. In August 2023, researchers from the University of Texas MD Anderson Cancer Center published their multicenter EXTEND trial findings. The results demonstrated that the addition of metastasis-directed radiation therapy to standard chemotherapy improves progression-free survival in patients suffering from oligometastatic pancreatic cancer. The addition of targeted radiation therapy increased the average progression-free survival by four times, showcasing the paradigm-shifting approach of the treatment for metastatic pancreatic cancer.

North America Holds Major Market Share of the Global Market

The rising cases of pancreatic cancer in the region, coupled with the strong presence of leading pharmaceutical companies and robust healthcare infrastructure, are propelling the growth of the North American pancreatic cancer treatment market. As per the estimates of the American Cancer Society, approximately 66,440 cases of pancreatic cancer are projected to be diagnosed in the United States in 2024. Additionally, the availability of government health insurance such as Medicaid and Medicare for qualifying individuals in the country increases the accessibility of the patient population suffering from chronic conditions, including pancreatic cancer, to various treatment options, further bolstering the market's demand in the region. Moreover, the presence of various organizations, such as the National Pancreatic Cancer Foundation (NPCF), that provide information to patients about medical providers and hospitals in their area along with additional assistance, including counseling, are also supporting the market's expansion. Furthermore, the easy availability of novel therapies and the high acceptance of novel treatment technologies in countries such as Canada and the United States are also positively influencing the expansion of the pancreatic cancer treatment market in the region.

Future Market Scenario (2024-2031F)

As per the global pancreatic cancer treatment market analysis, the market is expected to witness significant growth over the forecast period owing to the rising cases of pancreatic cancer and increasing investments by leading pharmaceutical companies toward the development and production of developing and producing novel therapeutic agents. As per the estimates of an article published in the World Journal of Gastroenterology, in 2050, pancreatic cancer incidences are estimated to increase to 18.6 per 100,000.

The major MedTech and biotech companies are also developing advanced diagnostic solutions to allow early-stage detection of pancreatic cancer, further augmenting the requirement for pancreatic cancer treatments. Advancements in immunotherapy, increasing research and development activities, and growing preference for targeted therapies are also expected to shape the market's landscape. Meanwhile, leading pharmaceutical companies across the globe are continuously working on assessing the safety and efficacy of a wide range of therapies for treating pancreatic cancer. For instance, Ono Pharmaceutical Co., Ltd. is conducting an interventional study to investigate the safety and tolerability of ONO-4538 and ONO-7913 in combination with modified FOLFIRINOX as a first-line treatment for metastatic pancreatic cancer. The study is expected to conclude in May 2025.

Key Players Landscape and Outlook

The key players in the market are actively investing in mergers and acquisitions to advance the development of pharmaceuticals for treating various cancer types. In May 2024, Mariana Oncology, Inc. (Mariana Oncology), a biotechnology company focusing on the innovation of radiopharmaceuticals for treating cancer patients, announced that they have been acquired by Novartis AG (Novartis) for up to USD 750 million in potential milestone payments and USD 1 billion upfront. This acquisition brings together Novartis's commercialization expertise and Mariana Oncology's innovative radiopharmaceutical pipeline, aiding the companies in transforming cancer care. This acquisition is also expected to provide Novartis with new capabilities in radioligand therapeutic research and complement their internal drug discovery and research efforts.

The leading market players are also working on introducing novel drugs for addressing the growing threat of pancreatic cancer. The continuous efforts of pharmaceutical companies across the globe to bolster the availability of treatment options for patients with pancreatic cancer are also supporting the market's expansion, with various drugs receiving approvals from different regulatory bodies. In February 2024, Ipsen Biopharmaceuticals, Inc.'s irinotecan liposome (Onivyde) with leucovorin, oxaliplatin, and fluorouracil was approved by the FDA as first-line treatment for metastatic pancreatic adenocarcinoma. The approval was supported by the results of NAPOLI 3, an open-label, randomized, active-controlled, and multicenter trial.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Pancreatic Cancer Treatment Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Cancer Type
  - 4.2.1.1. Endocrine Pancreatic Cancer
  - 4.2.1.2. Exocrine Pancreatic Cancer
- 4.2.2. By Treatment Type
  - 4.2.2.1. Chemotherapy
  - 4.2.2.2. Radiation Therapy
  - 4.2.2.3. Targeted Therapy
  - 4.2.2.4. Immunotherapy
  - 4.2.2.5. Hormone Therapy
  - 4.2.2.6. Others
- 4.2.3. By End-user
  - 4.2.3.1. Hospitals
  - 4.2.3.2. Clinics
  - 4.2.3.3. Cancer Care Centers
  - 4.2.3.4. Others
- 4.2.4. By Region
  - 4.2.4.1. North America
  - 4.2.4.2. Europe
  - 4.2.4.3. Asia-Pacific
  - 4.2.4.4. South America
  - 4.2.4.5. Middle East and Africa
- 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Cancer Type
- 4.3.2. By Treatment Type
- 4.3.3. By End-user
- 4.3.4. By Region

5. North America Pancreatic Cancer Treatment Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Cancer Type
  - 5.2.1.1. Endocrine Pancreatic Cancer
  - 5.2.1.2. Exocrine Pancreatic Cancer
- 5.2.2. By Treatment Type
  - 5.2.2.1. Chemotherapy
  - 5.2.2.2. Radiation Therapy
  - 5.2.2.3. Targeted Therapy
  - 5.2.2.4. Immunotherapy
  - 5.2.2.5. Hormone Therapy
  - 5.2.2.6. Others
- 5.2.3. By End-user
  - 5.2.3.1. Hospitals
  - 5.2.3.2. Clinics
  - 5.2.3.3. Cancer Care Centers
  - 5.2.3.4. Others
- 5.2.4. By Country Share
  - 5.2.4.1. United States
  - 5.2.4.2. Canada
  - 5.2.4.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Pancreatic Cancer Treatment Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Cancer Type
      - 5.3.1.2.1.1. Endocrine Pancreatic Cancer
      - 5.3.1.2.1.2. Exocrine Pancreatic Cancer
    - 5.3.1.2.2. By Treatment Type
      - 5.3.1.2.2.1. Chemotherapy
      - 5.3.1.2.2.2. Radiation Therapy
      - 5.3.1.2.2.3. Targeted Therapy
      - 5.3.1.2.2.4. Immunotherapy
      - 5.3.1.2.2.5. Hormone Therapy
      - 5.3.1.2.2.6. Others
    - 5.3.1.2.3. By End-user
      - 5.3.1.2.3.1. Hospitals
      - 5.3.1.2.3.2. Clinics
      - 5.3.1.2.3.3. Cancer Care Centers
      - 5.3.1.2.3.4. Others
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Pancreatic Cancer Treatment Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Pancreatic Cancer Treatment Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Pancreatic Cancer Treatment Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Pancreatic Cancer Treatment Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. AstraZeneca PLC
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 20.3.2. Pfizer Inc.
- 20.3.3. Teva Pharmaceutical Industries Ltd.
- 20.3.4. Novartis AG
- 20.3.5. Sanofi S.A.
- 20.3.6. GlaxoSmithKline plc
- 20.3.7. Merck & Co., Inc.
- 20.3.8. Bristol-Myers Squibb Company
- 20.3.9. Eli Lilly and Company
- 20.3.10. Takeda Pharmaceutical Company Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

簡介目錄圖表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 3. Global Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 4. Global Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 5. Global Pancreatic Cancer Treatment Market Share (%), By Region, 2017-2031F
Figure 6. North America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 7. North America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 8. North America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 9. North America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 10. North America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 11. United States Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 12. United States Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 13. United States Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 14. United States Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 15. Canada Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 16. Canada Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 17. Canada Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 18. Canada Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 19. Mexico Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 20. Mexico Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 21. Mexico Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 22. Mexico Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 23. Europe Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 24. Europe Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 25. Europe Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 26. Europe Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 27. Europe Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 28. Germany Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 29. Germany Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 30. Germany Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 31. Germany Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 32. France Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 33. France Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 34. France Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 35. France Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 36. Italy Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 37. Italy Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 38. Italy Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 39. Italy Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 40. United Kingdom Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 41. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 42. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 43. United Kingdom Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 44. Russia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 45. Russia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 46. Russia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 47. Russia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 48. Netherlands Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 49. Netherlands Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 50. Netherlands Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 51. Netherlands Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 52. Spain Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 53. Spain Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 54. Spain Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 55. Spain Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 56. Turkey Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 57. Turkey Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 58. Turkey Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 59. Turkey Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 60. Poland Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 61. Poland Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 62. Poland Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 63. Poland Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 64. South America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 65. South America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 66. South America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 67. South America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 68. South America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 69. Brazil Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 70. Brazil Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 71. Brazil Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 72. Brazil Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 73. Argentina Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 74. Argentina Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 75. Argentina Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 76. Argentina Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 77. Asia-Pacific Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 78. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 79. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 80. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 81. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 82. India Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 83. India Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 84. India Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 85. India Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 86. China Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 87. China Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 88. China Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 89. China Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 90. Japan Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 91. Japan Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 92. Japan Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 93. Japan Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 94. Australia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 95. Australia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 96. Australia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 97. Australia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 98. Vietnam Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 99. Vietnam Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 100. Vietnam Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 101. Vietnam Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 102. South Korea Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 103. South Korea Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 104. South Korea Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 105. South Korea Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 106. Indonesia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 107. Indonesia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 108. Indonesia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 109. Indonesia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 110. Philippines Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 111. Philippines Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 112. Philippines Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 113. Philippines Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 114. Middle East & Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 115. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 116. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 117. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 118. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 119. Saudi Arabia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 120. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 121. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 122. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 123. UAE Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 124. UAE Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 125. UAE Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 126. UAE Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 127. South Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 128. South Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 129. South Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 130. South Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 131. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 132. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023